165 related articles for article (PubMed ID: 12839430)
1. Rehospitalization risk with second-generation and depot antipsychotics.
Conley RR; Kelly DL; Love RC; McMahon RP
Ann Clin Psychiatry; 2003 Mar; 15(1):23-31. PubMed ID: 12839430
[TBL] [Abstract][Full Text] [Related]
2. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
Rabinowitz J; Lichtenberg P; Kaplan Z; Mark M; Nahon D; Davidson M
Am J Psychiatry; 2001 Feb; 158(2):266-9. PubMed ID: 11156809
[TBL] [Abstract][Full Text] [Related]
3. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of antipsychotic drugs.
Messori A
Am J Psychiatry; 2003 Mar; 160(3):591-2; author reply 592-3. PubMed ID: 12611854
[No Abstract] [Full Text] [Related]
5. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.
Olfson M; Marcus SC; Ascher-Svanum H
Schizophr Bull; 2007 Nov; 33(6):1379-87. PubMed ID: 17470444
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of antipsychotic drugs.
Meibach RC
Am J Psychiatry; 2003 Mar; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
[No Abstract] [Full Text] [Related]
7. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Moore DB; Kelly DL; Sherr JD; Love RC; Conley RR
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S17-9. PubMed ID: 9872689
[No Abstract] [Full Text] [Related]
8. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine.
Conley RR; Love RC; Kelly DL; Bartko JJ
Am J Psychiatry; 1999 Jun; 156(6):863-8. PubMed ID: 10360124
[TBL] [Abstract][Full Text] [Related]
9. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
[TBL] [Abstract][Full Text] [Related]
10. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Turner M; Eerdekens E; Jacko M; Eerdekens M
Int Clin Psychopharmacol; 2004 Jul; 19(4):241-9. PubMed ID: 15201572
[TBL] [Abstract][Full Text] [Related]
11. Depot bromperidol decanoate for schizophrenia.
Wong D; Adams CE; David A; Quraishi SN
Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Covell NH; McEvoy JP; Schooler NR; Stroup TS; Jackson CT; Rojas IA; Essock SM;
J Clin Psychiatry; 2012 May; 73(5):669-75. PubMed ID: 22480442
[TBL] [Abstract][Full Text] [Related]
13. Bromperidol decanoate (depot) for schizophrenia.
Purgato M; Adams CE
Cochrane Database Syst Rev; 2011 Sep; (9):CD001719. PubMed ID: 21901678
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
15. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
16. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine.
Werneck AP; Hallak JC; Nakano E; Elkis H
Psychiatry Res; 2011 Aug; 188(3):315-9. PubMed ID: 21596442
[TBL] [Abstract][Full Text] [Related]
17. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
18. New generation antipsychotics for first episode schizophrenia.
Rummel C; Hamann J; Kissling W; Leucht S
Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012
[TBL] [Abstract][Full Text] [Related]
19. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine.
Castro AP; Elkis H
Braz J Psychiatry; 2007 Sep; 29(3):207-12. PubMed ID: 17891257
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.
Shi L; Ascher-Svanum H; Zhu B; Faries D; Montgomery W; Marder SR
Psychiatr Serv; 2007 Apr; 58(4):482-8. PubMed ID: 17412849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
